What happens when a $2 million gene therapy is not enough

(This Aug. 12 story has been corrected to state that ICER's final analysis was that Zolgensma was cost effective at a price of $1.1 million to $1.9

Related Keywords

Kazakhstan ,Columbus ,Ohio ,United States ,Switzerland ,Berwyn ,Illinois ,Chicago ,Russia ,Virginia ,Lebanon ,Americans ,Deena Beasley ,Roger Hajjar ,Elizabeth Kutschke ,Roche Evrysdi ,Sitra Tauscher Wisniewski ,Amanda Cook ,Eric Cox ,Sree Chaguturu ,Sara Ledwith ,Vasant Narasimhan ,Maha Radhakrishnan ,Steven Pearson ,Stacie Dusetzina ,Ben Kutschke ,Caroline Humer ,Russell Butterfield ,Jerry Mendell ,Aetna ,Brigham Gene Cell Therapy Institute ,Novartis ,University Of Utah Health ,Institute For Human Data Science ,Institute For Clinical ,Unitedhealth Group ,Nashville Vanderbilt University School Of Medicine ,Drug Administration ,Reuters ,Baby Ben Kutschke ,Human Data ,Novartis Gene ,Mass General Brigham Gene ,Cell Therapy ,Vanderbilt University School ,Economic Review ,Chief Medical Officer Maha Radhakrishnan ,Nationwide Children ,Utah Health ,Intermountain Primary Children ,